| Autor: |
VASCONCELOS, Milena Rodrigues, FUMAGALLI, Renata Capelupe Simões, FUMAGALLI, Igor Henrique Teixeira, de MELO, Fábio Longarini Veríssimo, LEÓN, Jorge Esquiche, MARANGONI, Adriano Tadeu Dias, RANIERI, Ana Laura Polizel |
| Zdroj: |
Oral Surgery, Oral Medicine, Oral Pathology & Oral Radiology; Jun2024, Vol. 137 Issue 6, pe238-e238, 1p |
| Abstrakt: |
Mucormycosis is an aggressive fungal infection known for its rapid progression, particularly when it involves the oral cavity and potentially extends to the rhinocerebral region. Recently, the association between mucormycosis and post SARS-CoV-2 infection has gained clinical significance. In this report, we present two cases of acute invasive mucormycosis affecting the oral cavity following COVID-19 infection. Biopsies were conducted, and histopathological examinations confirmed the presence of Mucor spp. Subsequently, a multidisciplinary approach was undertaken, involving teams from Otorhinolaryngology, Head and Neck Surgery, Ophthalmology, and Dentistry. In one case, a provisional palatal obturator prosthesis was provided to enhance patient comfort. The Infectious Diseases team initiated treatment with ceftazidime at a dose of 2g per day for 5 days, followed by a transition to clindamycin (600mg every 8 hours) for approximately 2 months, in combination with ciprofloxacin. Additionally, liposomal amphotericin B was administered intravenously at a daily dose of 100mg for 4 months. These case reports underscore the importance of early detection of oral mucormycosis and provide valuable technical information to guide the management of patients affected by this condition, especially in the context of post-COVID-19 infections.. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full Text from ScienceDirect